Choisissez votre fonte :
 Arimo
 Merriweather
 Mukta Malar
 Open Sans Condensed
 Rokkitt
 Source Sans Pro
 Se connecter


 Français 
 English 
 Português 

[Valid RSS] RSS
bar

Base de données - Alliance francophone pour l'accouchement respecté (AFAR)

Présentation de cette base de données documentaires (site de l’AFAR)
Chaîne YouTube (tutoriel)

https://afar.info/id=453

Créée le : 10 Feb 2004
Modifiée le : 29 Dec 2018

 Modifier cette fiche
Ne suivez ce lien que si vous possédez un mot de passe d’éditeur !


Partager : Facebook logo   Tweeter logo   Tout public

Notice bibliographique (sans auteurs) :

Drugs, Pregnancy, and Lactation. Nonsteroidal Anti-Inflammatory Drugs. Ob.Gyn. News 2004;39(1):12.

Auteur·e(s) :

Briggs GG.

Année de publication :

2004

URL(s) :

http://highbeam.com/publications/ob-gyn-news-p883/…

Résumé (français)  :

Abstract (English)  :

Nonsteroidal anti-inflammatory drugs epitomize the well-known characterization of drugs as double-edged swords, as they have both beneficial and harmful edges. During pregnancy, the harmful edge primarily relates to embryonic/fetal toxicities, such as premature closure of the ductus arteriosus, renal toxicity, and spontaneous abortion.

There are 21 different NSAIDs on the market (including the prototypical aspirin), which are marketed under more than 30 different brand names and as numerous generic brands. Three NSAIDs, excluding aspirin, are available as over-the-counter products. Indications for NSAIDs encompass analgesia, inflammation, fever, prevention of cardiac disease, dysmenorrhea, tocolysis, and pharmacologic closure of patent ductus arteriosus in premature infants.

The therapeutic effects of NSAIDs are mediated through the inhibition of the cyclooxygenase-2 (COX-2) enzyme, which is irreversible with aspirin but reversible with other NSAIDs. The newer COX-2 inhibitors—celecoxib (Celebrex), rofecoxib (Vioxx), and valdecoxib (Bextra) —are promoted as having fewer adverse effects, such as GI toxicity and a reduced antiplatelet effect.

NSAIDs do not appear to be human teratogens. In some animal species, aspirin has been associated with a slight increase in malformations, including ventricular septal defect, midline defects (such as gastroschisis), and diaphragmatic hernia. Other NSAIDs have also been associated with anomalies, such as oral clefts, vertebral abnormalities, and other skeletal defects in animals.

But because of the omnipresence of aspirin and other NSAIDs, combined with the fact that most birth defects have no known cause, a low-level association with congenital malformations cannot be excluded.

The use of NSAIDs during pregnancy may be related to significant embryonic/fetal toxicity. Until recently, the major toxicity associated with exposure to NSAIDs during pregnancy was thought to be premature closure of the ductus arteriosus in utero. This effect is related to the dosage and duration of NSAID use and gestational age. For example, this risk is associated with NSAID use during the third trimester, beginning as early as 27 weeks and increasing markedly at 27-32 weeks.

The consequences of premature constriction of the ductus arteriosus may be persistent pulmonary hypertension of the newborn (PPHN), a severe effect that can be fatal. A 1996 case-control study of 103 infants found a highly significant association between PPHN and the use of aspirin or other NSAIDs during pregnancy. Short-term courses (such as 48 hours) of NSAIDs for tocolysis have not been associated with PPHN.

Continuous exposure to NSAIDs over at least several days during the third trimester has been related to fetal renal toxicity, as evidenced by a decrease in amniotic fluid. Although the renal toxicity is usually reversible, exposure to NSAIDs near delivery may result in poor neonatal outcomes.

Two recent studies have found a significant relationship between the use of NSAIDs in early gestation and spontaneous abortions. In a 2001 Danish study, a significant association was found in 63 women between the use of NSAIDs early in gestation and spontaneous abortion. The odds ratio was highest when drug exposure occurred close to the miscarriage, and decreased as the interval from exposure to the adverse event increased.

The second report, a prospective study published in August, involved more than 1,000 women in Northern California who were enrolled after they had a positive pregnancy test, at a median gestational age of 40 days. The risk of miscarriage in 53 women who reported use of NSAIDs—excluding aspirin—around conception or during pregnancy was 80% higher than that of 980 women who did not use NSAIDS or aspirin.

The strongest association was found when NSAIDs were used close to conception or when they were used for more than 1 week. Use of aspirin around conception by 22 women was also related to miscarriage, but the association was weaker because of the small number of women (BMJ 327 [7411] : 368, 2003).

Although more studies are needed to confirm the hypothesis that NSAIDs cause miscarriage, the available data suggest that clinicians should counsel women of reproductive age to avoid all NSAIDs (including aspirin) around the time when conception might occur through the end of the first trimester. Further, pregnant patients should be counseled to avoid NSAIDs during the last 4 months of gestation because of the proven risk of fetal toxicity.

Sumário (português)  :

Remarques :

Argument (français) :

Les données disponibles suggèrent que les cliniciens devraient conseiller les femmes en âge de procréer d’éviter tous les AINS (y compris l’aspirine) à peu près au moment où la conception pourrait survenir jusqu’à la fin du premier trimestre. En outre, il convient de conseiller aux patientes enceintes d’éviter les AINS au cours des 4 derniers mois de gestation en raison du risque avéré de toxicité fœtale.

Argument (English):

The available data suggest that clinicians should counsel women of reproductive age to avoid all NSAIDs (including aspirin) around the time when conception might occur through the end of the first trimester. Further, pregnant patients should be counseled to avoid NSAIDs during the last 4 months of gestation because of the proven risk of fetal toxicity.

Argumento (português):

Os dados disponíveis sugerem que os médicos devem aconselhar as mulheres em idade reprodutiva para evitar todos os AINEs (incluindo a aspirina) na época em que a concepção pode ocorrer até o final do primeiro trimestre. Além disso, pacientes grávidas devem ser aconselhadas a evitar AINEs durante os últimos 4 meses de gestação, devido ao risco comprovado de toxicidade fetal.

Mots-clés :

➡ allaitement ; douleur ; FCS fausse couche spontanée, fausse couche ; médicaments antidouleur

Auteur·e de cette fiche :

Cécile Loup — 10 Feb 2004
➡ dernière modification : Bernard Bel — 29 Dec 2018

Discussion (afficher uniquement le français)
 
➡ Réservé aux utilisateurs identifiés



 J'ai lu la charte des discussions et j'en accepte les conditions (voir la charte)

barre

Autre requête experte --- Autre requête simple

Création d'une fiche --- Importation de fiches

Gestion des utilisateurs --- Sauvegarder la base de données --- Contact

bar

Cette base de données est gérée par l'Alliance francophone pour l'accouchement respecté (AFAR, https://afar.info)
affiliée au Collectif interassociatif autour de la naissance (CIANE, http://ciane.net).
Elle est alimentée par les contributions de bénévoles intéressés par le partage des informations scientifiques.
Si vous approuvez ce projet, vous pouvez nous aider de plusieurs manières :
(1) devenir contributeur sur cette base, si vous avez un peu d'expérience en documentation
(2) ou soutenir financièrement l'AFAR (voir ci-dessous)
(3) ou devenir membre de l'AFAR (ou d'une autre association affiliée au CIANE).
Connectez-vous ou créez un compte pour suivre les modifications ou devenir éditrice.
Contactez afar.association(arobase)gmail.com pour plus d'informations.

Valid CSS! Valid HTML!
Nos ressources servent principalement à couvrir les frais d’hébergement des sites
et bases de données, l’impression de flyers et occasionnellement des frais de transport.
Les donateurs particuliers peuvent demander un reçu fiscal de l’AFAR donnant droit, en France, à une
réduction d’impôt égale à 66 % du montant dans la limite de 20% du revenu imposable (voir texte)